US4010282A - Anti-arrhythmic agents - Google Patents

Anti-arrhythmic agents Download PDF

Info

Publication number
US4010282A
US4010282A US05/590,156 US59015675A US4010282A US 4010282 A US4010282 A US 4010282A US 59015675 A US59015675 A US 59015675A US 4010282 A US4010282 A US 4010282A
Authority
US
United States
Prior art keywords
sup
dibenzyl
arrhythmic
sub
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US05/590,156
Inventor
Fritz Binnig
Manfred Raschack
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott GmbH and Co KG
Original Assignee
Knoll GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll GmbH filed Critical Knoll GmbH
Application granted granted Critical
Publication of US4010282A publication Critical patent/US4010282A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Definitions

  • the present invention relates to methods for treating arrhythmia with N,N'-dibenzyl alkylene diamines and to therapeutic compositions containing such compounds as an active ingredient.
  • the anti-arrhythmic agents heretofore used in therapy are accompanied by side effects, such as a negative influence on the contractile force of the heart, so that the use of these preparations is not without problems and involves a certain weighing of risks [cf., for example, Muertz et al., Med. Mschr. 24, 239-245 (1970) and Bleifeld et al., Dtsch. Med. Wschr. 96, 671-680 (1971)].
  • anti-arrhythmic agents which have a larger margin of safety between a dose which has an anti-arrhythmic effect and a dose having a negative inotropic effect, i.e., to develop agents which exhibit a greater therapeutic breadth than, for example, the well known substances such as antazoline, lidocaine, or N-propylajmaline.
  • the present invention relates more in particular to therapeutic agents which contain alkylene diamine compounds of the formula: ##STR2## wherein A, B, D, and E are the same or different and are hydrogen, chlorine, or methoxy, and wherein n is 2, 3, or 4, or their salts with physiologically-tolerable acids.
  • materials such as hydrochloric acid, sulfuric acid, phosphoric acid, acetic acid, malonic acid, succinic acid, maleic acid, citric acid, tartaric acid, lactic acid, and diamido sulfonic acid are exemplary.
  • alkylene diamine derivatives which for the most part are known in the art, can be prepared by reacting an ⁇ , ⁇ -dihaloalkane with benzylamine, which latter may be substituted, or by reacting an ⁇ , ⁇ -diaminoalkane with benzyl chloride, which may be substituted, or by reducing an ⁇ , ⁇ -di-(benzylideneamino)-alkane, which latter may also be substituted in the benzene rings.
  • the reaction of the amines with the halides can take place in the conventional manner in the presence or absence of a solvent.
  • Suitable solvents are, for example, inert hydrocarbons. It is particularly advantageous to use an excess of the amine component as the solvent.
  • the reaction can be carried out at temperatures from about 40° to about 250° C., preferably between 70° and 140° C.
  • the isolation of the reaction product suitably follows by distillation. It is recommended to convert the free bases so obtained into their salts which, in case it is necessary, can be further purified by recrystallization.
  • the reduction of dibenzylidene compounds can take place with the usual reducing agents such as platinum/hydrogen, lithium aluminum hydride, or sodium borohydride.
  • the evidence of the anti-arrhythmic effect of the new compounds can be demonstrated on experimental animals by determination of the functional refractory period of the left auricle of the guinea pig using paired electrical stimulation according to the method of W. C. Jovier, J. Pharmakol. Exp. Therap. 148, 100-105 (1965).
  • the numerous anti-arrhythmic agents, of different chemical structure and different therapeutic points of attack in man, heretofore used in therapy are all characterized by a lengthening of the functional refractory period.
  • the method additionally permits determining the effects of the substance on the contractile force of the heart muscle [Reuter and Heeg, Naunyn-Schmiedeberg's Arch. Pharmak.
  • Table 2 summarizes the good anti-arrhythmic efficacy of the diamines of the invention.
  • the N,N'-dibenzyl propylene diamine of Table 1 is also contained in Table 2.
  • the anti-arrhythmic effect of the diamines could also be confirmed in intact research animals with an experimentally-induced disturbance of the heart rhythm. If rats are continuously infused intravenously with aconitine, severe disturbances in the heartbeat sequence, such as extrasystoles, ventricular tachycardia, and ventricular flutter, which eventually lead to the death of the experimental animal, can be detected in an electrocardiogram. By a pre-treatment with the new pharmaceutical agents, the appearance of these threatening disturbances of the heart rhythm can be hindered or, on continuous administration of aconitine, can be considerably delayed.
  • Table 3 shows the results of tests on N,N'-dibenzyl propylene diamine.
  • the ED 25 and ED 50 are the intravenous or oral doses in mg/kg that permit a 25 percent or 50 percent increase in the dosage of aconitine administered, versus the aconitine control, until the occurrence of extrasystoles, ventricular tachycardia, and ventricular flutter.
  • This Table also shows the superior effect of the new pharmaceuticals, for example N,N'-dibenzyl propylene diamine-1,3, which can be administered parenterally as well as orally.
  • the alkylene diamine derivatives and their salts with physiologically-tolerable acids may be administered orally and parenterally.
  • the dose for intravenous or intramuscular administration is about 0.1-2.0 mg/kg per day and about 1-10 mg/kg per day for oral use.
  • the well known galenic dosage unit forms are suitable, such as tablets, dragees, capsules, and solutions.
  • 35.8 g of 1,3-dibromopropane are added dropwise to 100 g of 3-chlorobenzylamine with stirring at 90°-100° C. The mixture is then stirred for one hour at 130°-140° C. After cooling, a solution of 30 g of sodium hydroxide in 400 ml of water is added dropwise and then the mixture is extracted four times with 200 ml portions of diethyl ether. The ether extracts are dried over potassium hydroxide and concentrated. The residue is distilled in vacuum. At 166°-172° C., 0.05 mm Hg, 33.1 g of the desired compound distill over.
  • the compound so obtained is dissolved in isopropanol and, for salt formation, combined with a calculated amount of maleic acid.
  • Tablets are prepared in a conventional manner in a tablet press from the following composition:
  • the core mass comprises 9 parts of corn starch, 3 parts of lactose, and 1 part of a 60:40 vinyl pyrrolidone-vinyl acetate copolymer ("Luviscol VA 64"), cf. Pharm. Ind. 1962, 586.
  • the sugaring mass comprises 5 parts of cane sugar, 2 parts of corn starch, 2 parts of calcium carbonate, and 1 part of talc.
  • the dragees so prepared are subsequently coated with a coating resistant to stomach juices.
  • N,N'-dibenzyl-propylene diamine-di-maleinate 50 g are dissolved in 5 liters of water, isotonically adjusted with sodium chloride, and filled into ampules holding 5 ml.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Methods of treating cardiac arrhythmia by the oral or parenteral administration of N,N'-dibenzyl-alkylene diamine compounds of the formula ##STR1##or salts thereof with pharmaceutically acceptable acids, wherein A, B, D, and E are hydrogen, chlorine, or methoxy, and n is 2, 3, or 4; therapeutic compositions containing these anti-arrhythmic agents in combination with a pharmaceutical excipient.

Description

The present invention relates to methods for treating arrhythmia with N,N'-dibenzyl alkylene diamines and to therapeutic compositions containing such compounds as an active ingredient.
The anti-arrhythmic agents heretofore used in therapy are accompanied by side effects, such as a negative influence on the contractile force of the heart, so that the use of these preparations is not without problems and involves a certain weighing of risks [cf., for example, Muertz et al., Med. Mschr. 24, 239-245 (1970) and Bleifeld et al., Dtsch. Med. Wschr. 96, 671-680 (1971)]. Thus, it is desirable to develop anti-arrhythmic agents which have a larger margin of safety between a dose which has an anti-arrhythmic effect and a dose having a negative inotropic effect, i.e., to develop agents which exhibit a greater therapeutic breadth than, for example, the well known substances such as antazoline, lidocaine, or N-propylajmaline.
It has now been found that certain alkylene diamine compounds which have not heretofore been used therapeutically are suitable for the treatment of disturbances of cardiac function.
The present invention relates more in particular to therapeutic agents which contain alkylene diamine compounds of the formula: ##STR2## wherein A, B, D, and E are the same or different and are hydrogen, chlorine, or methoxy, and wherein n is 2, 3, or 4, or their salts with physiologically-tolerable acids.
As physiologically-tolerable acids, materials such as hydrochloric acid, sulfuric acid, phosphoric acid, acetic acid, malonic acid, succinic acid, maleic acid, citric acid, tartaric acid, lactic acid, and diamido sulfonic acid are exemplary.
The alkylene diamine derivatives, which for the most part are known in the art, can be prepared by reacting an α,ω-dihaloalkane with benzylamine, which latter may be substituted, or by reacting an α,ω-diaminoalkane with benzyl chloride, which may be substituted, or by reducing an α,ω-di-(benzylideneamino)-alkane, which latter may also be substituted in the benzene rings.
The reaction of the amines with the halides can take place in the conventional manner in the presence or absence of a solvent. Suitable solvents are, for example, inert hydrocarbons. It is particularly advantageous to use an excess of the amine component as the solvent. The reaction can be carried out at temperatures from about 40° to about 250° C., preferably between 70° and 140° C. The isolation of the reaction product suitably follows by distillation. It is recommended to convert the free bases so obtained into their salts which, in case it is necessary, can be further purified by recrystallization.
The reduction of dibenzylidene compounds can take place with the usual reducing agents such as platinum/hydrogen, lithium aluminum hydride, or sodium borohydride.
The evidence of the anti-arrhythmic effect of the new compounds can be demonstrated on experimental animals by determination of the functional refractory period of the left auricle of the guinea pig using paired electrical stimulation according to the method of W. C. Jovier, J. Pharmakol. Exp. Therap. 148, 100-105 (1965). In this experimental arrangement, the numerous anti-arrhythmic agents, of different chemical structure and different therapeutic points of attack in man, heretofore used in therapy are all characterized by a lengthening of the functional refractory period. The method additionally permits determining the effects of the substance on the contractile force of the heart muscle [Reuter and Heeg, Naunyn-Schmiedeberg's Arch. Pharmak. 268, 323-333 (1971) and Zetler and Strubelt, Naunyn-Schmiedeberg's Arch. Pharmak. 271, 335-345 (1971)]. It is, thus, highly suitable for detecting substances having a large therapeutic breadth, i.e., with a large margin of safety between anti-arrhythmically- and negative inotropically-effective doses.
The testing of the substances employed up to 30 individual experiments in each case. For the determination of the effective dose, linear regression functions were calculated [cf. A. Lindner, Statistische Methoden, 3rd Edition, Birkhaeuser Verlag, Basel (1969)], in which the maximum percentage deviations from the starting value in a time period up to 30 minutes after addition of the test substance to the bath liquid was employed.
In column I of following Table 1, one of the new compounds and known anti-arrhythmic agents are entered. Column II gives the anti-arrhythmic effect. Column III reports the inotropic effect. The therapeutic breadth of the compounds is given in column IV. The ED25 is the effective dose which lengthens the refractory period by 25 percent or lowers the contractile force by 25 percent. It is evident from the Table that the substance of the invention is clearly superior to the known substances from the point of view of the safety margin between the desired rhythm-regularizing effect and the undesirable influence on the contractility of the heart.
                                  TABLE I                                 
__________________________________________________________________________
              II           III                                            
I             Anti-arrhythmic Effect                                      
                           Inotropic Effect                               
                                      IV                                  
Anti-arrhythmic                                                           
              (Prolongation of the                                        
                           (Decrease in                                   
                                      Therapeutic Breadth                 
   Agent      Refractory Period)                                          
                           Contractile Force)                             
                                      (III/II)                            
__________________________________________________________________________
N,N'-dibenzyl-propylene-                                                  
              ED.sub.25 = 0.054                                           
                           ED.sub.25 = 0.141                              
                                      2.6                                 
   diamine-1,3                                                            
N,n-propylajmaline                                                        
              ED.sub.25 = 0.0037                                          
                           ED.sub.25 = 0.0015                             
                                      0.4                                 
Antazoline    ED.sub.25 = 0.164                                           
                           ED.sub.25 = 0.094                              
                                      0.6                                 
__________________________________________________________________________
Table 2 summarizes the good anti-arrhythmic efficacy of the diamines of the invention. The N,N'-dibenzyl propylene diamine of Table 1 is also contained in Table 2.
                                  TABLE 2                                 
__________________________________________________________________________
                         Dose  Anti-arrhythmic Effect (% Prolongation     
                         Mol/l of the Refractory Period)                  
__________________________________________________________________________
N,N'-dibenzyl-propylenediamine                                            
                         10.sup.-.sup.4                                   
                               47                                         
N,N'-dibenzyl-ethylenediamine                                             
                         10.sup.-.sup.4                                   
                               39                                         
N,N'-dibenzyl-butylenediamine                                             
                         10.sup.-.sup.4                                   
                               44                                         
N,N'-di-(m-chlorobenzyl)-propylenediamine                                 
                         2 × 10.sup.-.sup.5                         
                               45                                         
N,N'-di-(p-chlorobenzyl)-propylenediamine                                 
                         10.sup.-.sup.5                                   
                               37                                         
N,N'-di-(m,p-dichlorobenzyl)-propylenediamine                             
                         10.sup.-.sup.5                                   
                               26                                         
N,N'-di-(m-methoxybenzyl)propylenediamine                                 
                         5 × 10.sup.-.sup.5                         
                               40                                         
N,N'-di-(p-methoxybenzyl)-propylenediamine                                
                         10.sup.-.sup.4                                   
                               51                                         
N,N'-di-(m,p-dimethoxybenzyl)propylenediamine                             
                         10.sup.-.sup.4                                   
                               42                                         
__________________________________________________________________________
The anti-arrhythmic effect of the diamines could also be confirmed in intact research animals with an experimentally-induced disturbance of the heart rhythm. If rats are continuously infused intravenously with aconitine, severe disturbances in the heartbeat sequence, such as extrasystoles, ventricular tachycardia, and ventricular flutter, which eventually lead to the death of the experimental animal, can be detected in an electrocardiogram. By a pre-treatment with the new pharmaceutical agents, the appearance of these threatening disturbances of the heart rhythm can be hindered or, on continuous administration of aconitine, can be considerably delayed. This experimental model of arrhythmia has already been checked for its evidentiary value using clinically tested standard therapeutic agents and is highly suitable for an experimental animal characterization of anti-arrhythmic agents [cf. Bianchi et al., Arzneim. Forsch. 18, 845-850 (1968); Haas and Busch, Arzneim. Forsch. 18, 401-407 (1968); Haas et al., Arzneim. Forsch. 21, 1392-1399 (1971); Marmo, Naunyn-Schmiedeberg's Arch. Pharmak. 269, 231-247 (1971); and Strubelt et al., Naunyn-Schmiedeberg's Arch. Pharmak. 271, 346-360 (1971)].
Table 3 shows the results of tests on N,N'-dibenzyl propylene diamine. The ED25 and ED50 are the intravenous or oral doses in mg/kg that permit a 25 percent or 50 percent increase in the dosage of aconitine administered, versus the aconitine control, until the occurrence of extrasystoles, ventricular tachycardia, and ventricular flutter.
This Table also shows the superior effect of the new pharmaceuticals, for example N,N'-dibenzyl propylene diamine-1,3, which can be administered parenterally as well as orally.
                                  TABLE 3                                 
__________________________________________________________________________
               N,N'-DIBENZYL-PROPYLENEDIAMINE-1,3                         
                                     SPARTEINE                            
__________________________________________________________________________
               i.v.       p.o.       i.v.                                 
Extrasystoles                                                             
           ED.sub.25                                                      
               5.2        65.8       .sup.+)                              
           ED.sub.50                                                      
               6.0        96.2       .sup.+)                              
Ventr. Tachycardia                                                        
           ED.sub.25                                                      
               5.3        55.4       4.4                                  
           ED.sub.50                                                      
               6.2        71.6       9.6                                  
Ventr. Flutter                                                            
           ED.sub.25                                                      
               4.9        51.1       .sup.+)                              
           ED.sub.50                                                      
               6.4        69.9       .sup.+)                              
__________________________________________________________________________
 .sup.+) no significant effect attainable
The alkylene diamine derivatives and their salts with physiologically-tolerable acids may be administered orally and parenterally. The dose for intravenous or intramuscular administration is about 0.1-2.0 mg/kg per day and about 1-10 mg/kg per day for oral use. For administration, the well known galenic dosage unit forms are suitable, such as tablets, dragees, capsules, and solutions.
A better understanding of the present invention and of its many advantages will be had by referring to the following specific examples, given by way of illustration.
Preparation of the Compounds a. N,N'-di-(3'-chlorobenzyl)-propylene-1,3-diamine.
35.8 g of 1,3-dibromopropane are added dropwise to 100 g of 3-chlorobenzylamine with stirring at 90°-100° C. The mixture is then stirred for one hour at 130°-140° C. After cooling, a solution of 30 g of sodium hydroxide in 400 ml of water is added dropwise and then the mixture is extracted four times with 200 ml portions of diethyl ether. The ether extracts are dried over potassium hydroxide and concentrated. The residue is distilled in vacuum. At 166°-172° C., 0.05 mm Hg, 33.1 g of the desired compound distill over.
The compound so obtained is dissolved in isopropanol and, for salt formation, combined with a calculated amount of maleic acid. The isopropanol is distilled off and the residue, comprising N,N'-di-(3'-chlorobenzyl)-propylene-1,3-diamine-di-maleinate, is recrystallized from methanol/water. m.p. = 203°-204° C.
b. N,N'-di-(4'-chlorobenzyl)-1,3-diaminopropane.
A solution of 54.7 g of N,N'-di-(4-chlorobenzylidene)-1,3-diaminopropane in 1 liter of methanol is combined in an ice bath, with stirring, with 19.1 g of sodium borohydride. After addition of the hydride, the mixture is stirred for a further hour and then refluxed at the boiling point for an additional 1/2 hour.
After cooling, 1 liter of 10 percent sodium hydroxide is added, the mixture is shaken four times with 100 ml portions of diethyl ether, and the ether extracts are dried over sodium hydroxide. After distilling off the ether, 47 g of a colorless oil are obtained by vacuum distillation at 180° C/0.01 mm Hg. The oil has an index of refraction ND 25 = 1.5715. The di-maleinate, prepared as in part (a), melts at 219°-220° C.
EXAMPLE 1
Tablets are prepared in a conventional manner in a tablet press from the following composition:
70.00 mg of N,N'-dibenzyl-propylene diamine-dihydrochloride
50.00 mg of corn starch
4.50 mg of gelatin
15.00 mg of lactose
7.50 mg of talc
0.75 mg of chemically pure submicroscopically-divided silicic acid ("Aerosil")
2.25 mg of potato starch (as a 6 percent paste).
EXAMPLE 2
Dragees of the following composition are prepared in the usual manner:
50.00 mg of N,N'-dibenzyl-propylene diamine
85.00 mg of corn mass
80.00 mg of sugaring mass
The core mass comprises 9 parts of corn starch, 3 parts of lactose, and 1 part of a 60:40 vinyl pyrrolidone-vinyl acetate copolymer ("Luviscol VA 64"), cf. Pharm. Ind. 1962, 586. The sugaring mass comprises 5 parts of cane sugar, 2 parts of corn starch, 2 parts of calcium carbonate, and 1 part of talc. The dragees so prepared are subsequently coated with a coating resistant to stomach juices.
EXAMPLE 3
50 g of N,N'-dibenzyl-propylene diamine-di-maleinate are dissolved in 5 liters of water, isotonically adjusted with sodium chloride, and filled into ampules holding 5 ml.

Claims (3)

What is claimed is:
1. The method of treating cardiac arrhythmia in a patient suffering therefrom which comprises orally or parenterally administrating a therapeutically effective amount of an N,N'-dibenzyl alkylene diamine compound of the formula ##STR3## or of a salt thereof with a physiologically tolerable acid, wherein A, B, D, and E are hydrogen, chlorine, or methoxy, and n is 2, 3, or 4.
2. The method as in claim 1 wherein from 0.1-2.0 mg/kg/day of said compound or salt are parenterally administered.
3. The method as in claim 1 wherein from 1-10 mg/kg/day of said compound or salt are administered orally.
US05/590,156 1974-08-09 1975-06-25 Anti-arrhythmic agents Expired - Lifetime US4010282A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE2438288A DE2438288A1 (en) 1974-08-09 1974-08-09 NEW ANTIARRHYTHMICS
DT2438288 1974-08-09

Publications (1)

Publication Number Publication Date
US4010282A true US4010282A (en) 1977-03-01

Family

ID=5922788

Family Applications (1)

Application Number Title Priority Date Filing Date
US05/590,156 Expired - Lifetime US4010282A (en) 1974-08-09 1975-06-25 Anti-arrhythmic agents

Country Status (6)

Country Link
US (1) US4010282A (en)
BE (1) BE832121A (en)
DE (1) DE2438288A1 (en)
FR (1) FR2281106A1 (en)
GB (1) GB1471089A (en)
NL (1) NL7508325A (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4448776A (en) * 1981-02-12 1984-05-15 Karl Bucher Method of using certain substituted aliphatic secondary amines or their salts for easing breathing
US4645768A (en) * 1983-01-21 1987-02-24 Fisons Plc Formulations
WO2013184202A1 (en) * 2012-06-08 2013-12-12 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Fbxo3 inhibitors
JP2017521392A (en) * 2014-06-16 2017-08-03 ユニヴェルシテ・ドゥ・リール・２・ドロワ・エ・サンテ Compounds, pharmaceutical compositions and their use in the treatment of neurodegenerative diseases
US9849098B2 (en) 2013-12-09 2017-12-26 University of Pittsburgh—of the Commonwealth System of Higher Education Compositions and methods for treating respiratory injury or disease
US10487076B2 (en) 2014-12-10 2019-11-26 University of Pittsburgh—of the Commonwealth System of Higher Education Compositions and methods for treating diseases and conditions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J. Med. Chem., 7(4), 500-503, (1964); vol. 8(3), (1965), 401-404. *
J. Med. Chem., 9(3), 329-334, (1966). *

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4448776A (en) * 1981-02-12 1984-05-15 Karl Bucher Method of using certain substituted aliphatic secondary amines or their salts for easing breathing
US4645768A (en) * 1983-01-21 1987-02-24 Fisons Plc Formulations
US10369150B2 (en) 2012-06-08 2019-08-06 University of Pittsburgh—of the Commonwealth System of Higher Education Benzathine analogs
WO2013184202A1 (en) * 2012-06-08 2013-12-12 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Fbxo3 inhibitors
CN104684895A (en) * 2012-06-08 2015-06-03 高等教育联邦系统-匹兹堡大学 FBXO3 inhibitors
JP2015520187A (en) * 2012-06-08 2015-07-16 ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション FBXO3 inhibitor
US9359284B2 (en) 2012-06-08 2016-06-07 University of Pittsburgh—of the Commonwealth System of Higher Education Benzathine analogs
US11857550B2 (en) 2012-06-08 2024-01-02 University of Pittsburgh—of the Commonwealth System of Higher Education Benzathine analogs
US10869866B2 (en) 2012-06-08 2020-12-22 University of Pittsburgh—of the Commonwealth System of Higher Education Benzathine analogs
US10159674B2 (en) 2012-06-08 2018-12-25 University of Pittsburgh—of the Commonwealth System of Higher Education Benzathine analogs
US10307423B2 (en) 2012-06-08 2019-06-04 University Of Pittsburgh - Of The Commonwealth System Of Higher Education FBXO3 inhibitors
US10092526B2 (en) 2013-12-09 2018-10-09 University of Pittsburgh—of the Commonwealth System of Higher Education Compositions and methods for treating respiratory injury or disease
US9849098B2 (en) 2013-12-09 2017-12-26 University of Pittsburgh—of the Commonwealth System of Higher Education Compositions and methods for treating respiratory injury or disease
US10844008B2 (en) 2014-06-16 2020-11-24 Universite De Lille 2 Droit Et Sante Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
JP2017521392A (en) * 2014-06-16 2017-08-03 ユニヴェルシテ・ドゥ・リール・２・ドロワ・エ・サンテ Compounds, pharmaceutical compositions and their use in the treatment of neurodegenerative diseases
US10487076B2 (en) 2014-12-10 2019-11-26 University of Pittsburgh—of the Commonwealth System of Higher Education Compositions and methods for treating diseases and conditions
US11072606B2 (en) 2014-12-10 2021-07-27 University of Pittsburgh—of the Commonwealth System of Higher Education Compositions and methods for treating diseases and conditions

Also Published As

Publication number Publication date
GB1471089A (en) 1977-04-21
BE832121A (en) 1976-02-05
DE2438288A1 (en) 1976-02-19
FR2281106A1 (en) 1976-03-05
NL7508325A (en) 1976-02-11

Similar Documents

Publication Publication Date Title
US3505337A (en) N - hydrocarbyl-substituted noratropinium,haloalkylates and o-acyl derivatives thereof
US4632934A (en) Imidazole derivatives and pharmaceutical use thereof
US3962449A (en) Cardioactive bispidones and bispidines
US3968243A (en) Substituted guanidine compounds in the treating of arrythmias
US4459301A (en) Method of treating cardiac disorders using bispidine derivatives
EP0282547A1 (en) Method for controlling emesis caused by chemotherapeutic agents and antiemetic agents useful therein.
US4010282A (en) Anti-arrhythmic agents
EP0155653B1 (en) Substituted (azacycloalk-2-yl) iminophenols and esters thereof
US3637803A (en) Alkyl methylsulfonylalkyl benzoates
KR100352899B1 (en) Pharmaceuticals containing novel 3-phenylsulfonyl-3,7-diazabicyclo [3,3,1] nonan-compounds
US4277501A (en) Para-nitrophenylalkylamines and pharmaceutical compositions
SU1609453A3 (en) Method of producing derivatives of gidantoine
US3966745A (en) Vinvamine series cycloalkyl-alkyl esters
US4109005A (en) Method of increasing rate of gastric emptying with pyrrolidinylbenzamides
US4031216A (en) 3-(3,4-Dialkoxy-benzyl)-3-methyl-piperazines
US3708598A (en) Substituted 2,4-(omega-aminoalkoxy)phenyl imidazoles as cholesterol reducing agents
WO1992006955A1 (en) Melatonin derivative having therapeutic activity in dermatology
US4415495A (en) 5,6;8,9-Tetrahydro-7H-dibenz(d,f)azonines
US3105006A (en) Novel nu-arylsulfonyl-nu'-(1, 2, 3, 6-tetrahydro-1-pyridyl) ureas and oral antidiabetic compositions
US3996360A (en) Piperazine compounds
EP0280290B1 (en) Agent having an antidepressive activity
JPH03167184A (en) N-benzyltropane amides
US3884954A (en) 12-Cyano-5,6,7,12-tetrahydrodibenzo{8 a,d{9 cyclooctenes
US4259354A (en) Method of treating arrhythmia
US3855283A (en) Levo 1-amino-3-chloro-2-propanol and acid addition salts thereof